MRNA analyst scorecard · Moderna
38 rating actions on MRNA in the last 12 months. Of 42 price targets that resolved, 16 were reached while they stood, 24 were replaced by the same firm first, and 2 fell short at their deadline. Ratings: 16% Buy-type, 66% Hold-type, 18% Sell-type. Consensus target $138, 37% below the last close.
Checked through 2026-10-29 · last close $218.83 (2026-10-29). Rebuilt every morning.
What the Holds say: 23 Hold-type ratings on MRNA in the last 12 months carried a median target -7% from the price on the day; 65% sat below it.
The 3 upgrades on MRNA came after an average +180.0% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| UBS | Neutral | 2026-08-20 | $150 | 2 | 3 | 5 | 0 of 1 |
| Argus Research | Buy | 2026-08-28 | $180 | 1 | 0 | 1 | — |
| Wolfe Research | Peer Perform | 2026-08-25 | — | 1 | 0 | 1 | 1 of 1 |
| Piper Sandler | Overweight | 2026-10-26 | $230 | 1 | 2 | 4 | 0 of 1 |
| Goldman Sachs | Neutral | 2026-10-15 | $137 | 1 | 2 | 3 | — |
| Morgan Stanley | Equal-Weight | 2026-10-07 | $95 | 2 | 3 | 5 | — |
| RBC Capital | Sector Perform | 2026-07-07 | $45 | 1 | 3 | 4 | — |
| Bank of America | Underperform | 2026-07-07 | $38 | 2 | 2 | 4 | 0 of 1 |
| Barclays | Equal-Weight | 2026-08-24 | $125 | 0 | 4 | 4 | — |
| William Blair | Market Perform | 2026-10-27 | — | — | — | 0 | — |
| Citigroup | Sell | 2026-09-30 | $80 | 2 | 1 | 3 | — |
| Evercore ISI Group | In-Line | 2026-05-04 | $50 | 2 | 2 | 4 | — |
| TD Cowen | Hold | 2026-10-21 | $90 | — | — | 0 | — |
| Rothschild & Co | Sell | 2026-09-03 | $81 | — | — | 0 | — |
| JPMorgan | Underweight | 2026-08-21 | $77 | 1 | 1 | 2 | 1 of 1 |
| Jefferies | Hold | 2025-12-12 | $30 | — | — | 0 | — |
| Leerink Partners | Underperform | 2025-11-21 | $18 | 0 | 1 | 1 | 0 of 1 |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor MRNA carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-27 | William Blair | Outperform → Market Perform | downgrade | $207.97 | — | no target | +4.6% |
| 2026-10-26 | Piper Sandler | Overweight | reiterated | $198.85 | $230 | running to 2027-10-26 | -0.0% |
| 2026-10-21 | TD Cowen | Hold | maintained | $245.81 | $90 | running to 2027-10-21 | +42.1% |
| 2026-10-15 | Goldman Sachs | Neutral | maintained | $236.50 | $137 | running to 2027-10-15 | +64.5% |
| 2026-10-07 | Morgan Stanley | Equal-Weight | maintained | $196.48 | $95 | running to 2028-04-07 | +35.0% |
| 2026-09-30 | Citigroup | Neutral → Sell | downgrade | $192.57 | $80 | running to 2027-09-30 | +37.2% |
| 2026-09-03 | Rothschild & Co | Neutral → Sell | downgrade | $148.87 | $81 | running to 2027-09-03 | +161.2% |
| 2026-08-28 | Argus Research | Hold → Buy | upgrade | $137.99 | $180 | reached 2026-09-22 | +153.2% |
| 2026-08-25 | Wolfe Research | Underperform → Peer Perform | upgrade | $158.83 | — | no target | +193.8% |
| 2026-08-24 | Barclays | Equal-Weight | maintained | $138.89 | $125 | running to 2027-08-24 | +156.9% |
| 2026-08-21 | JPMorgan | Underweight | maintained | $145.13 | $77 | running to 2027-08-21 | +149.9% |
| 2026-08-20 | Goldman Sachs | Neutral | maintained | $133.32 | $120 | replaced 2026-10-15, new $137 | +123.5% |
| 2026-08-20 | UBS | Neutral | maintained | $133.32 | $150 | reached 2026-08-25 | +123.5% |
| 2026-08-20 | Morgan Stanley | Equal-Weight | maintained | $133.32 | $89 | replaced 2026-10-07, new $95 | +123.5% |
| 2026-08-19 | William Blair | Market Perform → Outperform | upgrade | $174.38 | — | no target | +193.1% |
| 2026-08-03 | Citigroup | Neutral | maintained | $55.14 | $60 | reached 2026-08-11 | -30.9% |
| 2026-07-21 | Goldman Sachs | Neutral | maintained | $59.66 | $67 | reached 2026-08-19 | -6.7% |
| 2026-07-08 | Morgan Stanley | Equal-Weight | maintained | $73.80 | $39 | replaced 2026-08-20, new $89 | +55.0% |
| 2026-07-07 | RBC Capital | Sector Perform | maintained | $79.77 | $45 | running to 2027-07-07 | +68.2% |
| 2026-07-07 | Bank of America | Underperform | maintained | $79.77 | $38 | running to 2027-07-07 | +68.2% |
| 2026-06-26 | Piper Sandler | Overweight | maintained | $67.27 | $77 | reached 2026-07-02 | +41.3% |
| 2026-06-08 | Bank of America | Underperform | maintained | $47.60 | $34 | replaced 2026-07-07, new $38 | -12.4% |
| 2026-05-04 | UBS | Neutral | maintained | $47.30 | $45 | within 5% of price when set | -3.9% |
| 2026-05-04 | Goldman Sachs | Neutral | maintained | $47.30 | $49 | within 5% of price when set | -3.9% |
| 2026-05-04 | Evercore ISI Group | In-Line | maintained | $47.30 | $50 | reached 2026-05-08 | -3.9% |
| 2026-05-04 | RBC Capital | Sector Perform | maintained | $47.30 | $38 | replaced 2026-07-07, new $45 | -3.9% |
| 2026-04-02 | Barclays | Equal-Weight | maintained | $49.20 | $48 | within 5% of price when set | -1.3% |
| 2026-02-23 | Piper Sandler | Overweight | maintained | $50.29 | $69 | replaced 2026-06-26, new $77 | +3.2% |
| 2026-02-17 | Goldman Sachs | Neutral | maintained | $43.93 | $41 | replaced 2026-05-04, new $49 | +5.0% |
| 2026-02-17 | RBC Capital | Sector Perform | maintained | $43.93 | $30 | replaced 2026-05-04, new $38 | +5.0% |
| 2026-02-17 | Evercore ISI Group | In-Line | maintained | $43.93 | $35 | replaced 2026-05-04, new $50 | +5.0% |
| 2025-12-12 | Morgan Stanley | Equal-Weight | maintained | $29.46 | $28 | within 5% of price when set | +10.3% |
| 2025-12-12 | Jefferies | Hold | initiated | $29.46 | $30 | within 5% of price when set | +10.3% |
| 2025-11-21 | Piper Sandler | Overweight | reiterated | $23.72 | $63 | replaced 2026-02-23, new $69 | — |
| 2025-11-21 | RBC Capital | Sector Perform | maintained | $23.72 | $25 | reached 2025-11-26 | — |
| 2025-11-21 | Leerink Partners | Underperform | maintained | $23.72 | $18 | running to 2026-11-21 | — |
| 2025-11-10 | Bank of America | Underperform | maintained | $24.76 | $21 | replaced 2026-06-08, new $34 | — |
| 2025-11-07 | Barclays | Equal-Weight | maintained | $24.54 | $25 | within 5% of price when set | — |
Also in Biotech
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.